Caffeine for Prevention of Alzheimer’s Disease: Is the A_2A Adenosine Receptor Its Target?

Alzheimer’s disease (AD) is the most prevalent kind of dementia with roughly 135 million cases expected in the world by 2050. Unfortunately, current medications for the treatment of AD can only relieve symptoms but they do not act as disease-modifying agents that can stop the course of AD. Caffeine...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Stefania Merighi, Alessia Travagli, Manuela Nigro, Silvia Pasquini, Martina Cappello, Chiara Contri, Katia Varani, Fabrizio Vincenzi, Pier Andrea Borea, Stefania Gessi
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	MDPI AG 2023-06-01
Σειρά:	Biomolecules
Θέματα:	A<sub>2A</sub> adenosine receptor Alzheimer’s disease amyloid beta caffeine neuroinflammation therapeutic target
Διαθέσιμο Online:	https://www.mdpi.com/2218-273X/13/6/967
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!